BAY 3670549
Alternative Names: BAY-3670549Latest Information Update: 02 Jul 2025
At a glance
- Originator Bayer
- Class Antiarrhythmics; Cardiovascular therapies
- Mechanism of Action G protein-coupled inwardly-rectifying potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atrial fibrillation